Ignite Creation Date:
2025-12-24 @ 5:26 PM
Ignite Modification Date:
2026-01-06 @ 4:37 AM
Study NCT ID:
NCT00278668
Status:
UNKNOWN
Last Update Posted:
2008-05-21
First Post:
2006-01-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ECT Schizophrenia Serotonin Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 15}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2006-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2008-05', 'completionDateStruct': {'date': '2006-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2008-05-20', 'studyFirstSubmitDate': '2006-01-16', 'studyFirstSubmitQcDate': '2006-01-16', 'lastUpdatePostDateStruct': {'date': '2008-05-21', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-01-18', 'type': 'ESTIMATED'}}, 'conditionsModule': {'conditions': ['Schizophrenia']}, 'descriptionModule': {'briefSummary': 'We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT', 'detailedDescription': 'We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nParticipants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).\n\nAges 18 -55 Men and/or women -\n\nExclusion Criteria:\n\n1. History of neurological disorders, active substance abuse in the previous 3 months.\n2. Estimated IQ less then 70.\n3. SSRIs treatment 4 weeks prior to the study.\n4. Any subject suffering from inflammatory fever disease will be excluded from the study.\n\n \\-'}, 'identificationModule': {'nctId': 'NCT00278668', 'briefTitle': 'ECT Schizophrenia Serotonin Study', 'organization': {'class': 'OTHER', 'fullName': "Sha'ar Menashe Mental Health Center"}, 'officialTitle': 'Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy', 'orgStudyIdInfo': {'id': '123.ctil'}}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Avi Peled, MD', 'role': 'CONTACT', 'email': 'av_peled@netvision.net.il', 'phone': '972522844050'}], 'overallOfficials': [{'name': 'Avi Peled, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shaar Menashe MHC'}, {'name': 'Ilan Modai, M.D. MHA', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shaar Menashe'}, {'name': 'Moshe Rehavi, Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TAU'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Sha'ar Menashe Mental Health Center", 'class': 'OTHER'}}}}